70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Review, H1 2016

  • ID: 3802740
  • Report
  • 42 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • ArQule, Inc.
  • Eddingpharm
  • Merck KGaA
  • PharmAust Limited
  • Sentinel Oncology Limited
  • MORE
70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Review, H1 2016

Summary

‘70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Review, H1 2016’, provides in depth analysis on 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1)
- The report reviews 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ArQule, Inc.
  • Eddingpharm
  • Merck KGaA
  • PharmAust Limited
  • Sentinel Oncology Limited
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) Overview

Therapeutics Development

70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Products under Development by Stage of Development

70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Products under Development by Therapy Area

70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Products under Development by Indication

70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Products Glance

Late Stage Products

Early Stage Products

70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Products under Development by Companies

70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Companies Involved in Therapeutics Development

ArQule, Inc.

Astex Pharmaceuticals, Inc.

Eddingpharm

Merck KGaA

PharmAust Limited

Phoenix Biotechnology, Inc.

Sentinel Oncology Limited

70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Drug Profiles

AT-13148 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EDP-317 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-2698 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

monepantel - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBI-05204 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule To Inhibit S6K1 For Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit S6K for Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Dormant Projects

70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Discontinued Products

70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Featured News & Press Releases

Jan 29, 2016: PharmAust Limited Announced Quarterly Report & Company Update For the period ended 31 December 2015

Nov 26, 2015: PharmAust Appoints GenScript to Complete Further Pre-Clinical Validation for Phase II Trial

Jan 17, 2013: Cancer Research UK And Cancer Research Technology Launches Phase I Clinical Trial With AT13148 To Treat Several Cancer Types

Jan 16, 2013: Astex Pharma Announces Cancer Research UK And Cancer Research Technology Initiate AT13148 Clinical Trial To Treat Several Cancer Types

Jul 10, 2012: Experimental Drug Could Treat Different Cancers, New Research Says

Jan 22, 2010: ACT BIOTECH Announces FDA Acceptance Of IND For ACTB1003, A First-in-Class Anti-Cancer Therapeutic

Oct 18, 2007: Astex Drug Candidates To Be Featured At The 2007 AACR-NCI-EORTC International Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 42List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by ArQule, Inc., H1 2016

Pipeline by Astex Pharmaceuticals, Inc., H1 2016

Pipeline by Eddingpharm, H1 2016

Pipeline by Merck KGaA, H1 2016

Pipeline by PharmAust Limited, H1 2016

Pipeline by Phoenix Biotechnology, Inc., H1 2016

Pipeline by Sentinel Oncology Limited, H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016 35List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • ArQule, Inc.
  • Eddingpharm
  • Merck KGaA
  • PharmAust Limited
  • Sentinel Oncology Limited
  • MORE
70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies.The author's latest report 70-kDa Ribosomal Protein S6 Kinase - Pipeline Review, H1 2016, outlays comprehensive information on the 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) p70S6K or Ribosomal protein S6 kinase beta-1 (S6K1) is an enzyme encoded by the RPS6KB1 gene. p70S6K plays a crucial role in controlling cell cycle, growth and survival. The PI3K/mTOR signaling pathway is one of the major mechanisms for controlling cell survival, proliferation and metabolism and is the central regulator of translation of some components of protein synthesis system. Due to the role of p70S6K in protein synthesis it is involvement in a variety of diseases ranging from diabetes and obesity to cancer. The molecules developed by Companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 2, 1 and 2 respectively.

Furthermore, this report also reviews key players involved in 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
ArQule, Inc.
Astex Pharmaceuticals, Inc.
Eddingpharm
Merck KGaA
PharmAust Limited
Phoenix Biotechnology, Inc.
Sentinel Oncology Limited
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll